{"id":15378,"date":"2012-09-13T16:30:00","date_gmt":"2012-09-13T14:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/pfizer-avvia-joint-venture-in-cina-con-hisun\/"},"modified":"2012-09-13T16:30:00","modified_gmt":"2012-09-13T14:30:00","slug":"pfizer-avvia-joint-venture-in-cina-con-hisun","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/pfizer-avvia-joint-venture-in-cina-con-hisun\/","title":{"rendered":"Pfizer launches joint venture in China with Hisun"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: right; line-height: normal; margin: 0cm 0cm 0pt\"><i><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><img loading=\"lazy\" decoding=\"async\" id=\"il_fi\" alt=\"\" width=\"129\" height=\"170\" style=\"padding-bottom: 8px; padding-right: 8px; padding-top: 8px\" src=\"http:\/\/image.made-in-china.com\/0f0j00tMvTUBecbVqC\/Zhejiang-Hisun-Pharmaceutical-Co-Ltd-.jpg\" \/><\/span><\/i><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt\"><i><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">The joint venture is for the development, manufacturing and marketing of generic drugs in China and world markets with an investment of US$295 million<\/span><\/i><span style=\"font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; font-size: 12pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><\/p>\n<p><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">Pfizer has entered into a joint venture with Chinese pharmaceutical company Zhejiang Hisun Pharmaceuticals to develop, manufacture and commercialize generic drugs in China and worldwide markets with an investment of $295 million. Hisun-Pfizer Pharmaceuticals has a registered capital of $250 million, with Hisun controlling 51% and Pfizer controlling 49%. The off-patent medicines sector is a rapidly growing segment, especially in emerging markets, Pfizer said in a statement. The US pharmaceutical company estimated that in China, own-brand generics account for 70% of the domestic pharmaceutical market. &quot;The joint venture is a milestone in Pfizer&#039;s commitment to China&#039;s healthcare reforms and expanding the reach of its products in China,&quot; said Xiaobing Wu, Pfizer country manager for China.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><i style=\"mso-bidi-font-style: normal\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">13 September 2012 \u2013 Milan Finance<\/p>\n<p><\/span><\/i><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>La joint venture &egrave; per lo sviluppo, la produzione e la commercializzazione di farmaci generici in Cina e sui mercati mondiali con un investimento di 295 milioni di dollari Pfizer ha avviato una joint venture con la societ&agrave; farmaceutica cinese Zhejiang Hisun Pharmaceuticals per lo sviluppo, la produzione e la commercializzazione di farmaci generici in &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15378","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15378"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15378\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}